高级检索
当前位置: 首页 > 详情页

Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Capital Med Univ, Beijing Friendship Hosp, Dept Nephrol, Beijing 100050, Peoples R China
出处:
ISSN:

关键词: Piperlongumine Lupus MRL-Fas(lpr) mice Th17 Regulatory T cells

摘要:
Recent data have shown that piperlongumine (PL), an important component of Piper longum fruits, is known to possess anti-inflammatory and vascular-protective activities. This study aimed to examine the therapeutic effects and underlying mechanisms of PL on lupus-prone MRL-Fas(lpr) mice. Female MRL-Fas(lpr) mice were intraperitoneally treated with PL (2.4 mg kg(-1) d(-1)) for 10 weeks, and the proteinuria level was biweekly monitored. After the mice were euthanized, serum biochemical parameters and renal damage were determined. Splenocytes of MRL-Fas(lpr) mice were isolated for in vitro study. Treatment of the mice with PL significantly attenuated the progression of proteinuria and glomerulonephritis. The improvement was accompanied by decreased serum levels of nephritogenic anti-dsDNA antibodies, IL-6, IL-17, IL-23 and TNF-alpha.. Treatment of the mice with PL suppressed the frequency of Th17 cells and increased the regulatory T cells (Tregs). In vitro, the levels of IL-6, IL-17, IL-23 and TNF-alpha were significantly decreased in the cultures of splenocytes from PL-treated mice compared with those from vehicle-treated mice. In addition, PL treatment impeded activation of the JAK/STAT3 signaling in splenocytes. Of great important, the survival of MRL-Fas(lpr) mice were improved by PL treatment. In summary, PL effectively ameliorates lupus syndrome in MRL-Fas(lpr) mice by suppressing the pathogenic Th17 cells and increasing the Tregs as well as inhibiting activation of the JAK/STAT3 signaling pathway. This study sheds new light on the immune-modulatory role of PL. (C) 2014 Elsevier B.V. All rights reserved.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 3 区 医学
小类 | 4 区 免疫学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 免疫学
JCR分区:
出版当年[2012]版:
Q3 IMMUNOLOGY
最新[2023]版:
Q3 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2012版] 出版当年五年平均[2008-2012] 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者单位: [1]Capital Med Univ, Beijing Friendship Hosp, Dept Nephrol, Beijing 100050, Peoples R China
通讯作者:
通讯机构: [1]Capital Med Univ, Beijing Friendship Hosp, Dept Nephrol, Beijing 100050, Peoples R China [*1]Capital Med Univ, Beijing Friendship Hosp, Dept Nephrol, 95 Yong An Rd, Beijing 100050, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:817 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)